JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cabral, A. M.
Right arrow Articles by Kapusta, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cabral, A. M.
Right arrow Articles by Kapusta, D. R.

Vol. 282, Issue 2, 609-616, 1997

Renal Excretory Responses Produced by Central Administration of Opioid Agonists in Ketamine and Xylazine-Anesthetized Rats1

Antonio M. Cabral, Kurt J. Varner and Daniel R. Kapusta

Department of Physiological Sciences, Federal University of Espirito Santo, Brazil (A.-M.C.) and the Department of Pharmacology and Experimental Therapeutics (K.J.V., D.R.K.), Louisiana State University Medical Center, New Orleans, Louisiana

This study examined the renal excretory responses produced by the intravenous (i.v.) infusion of the alpha-2 agonist, xylazine, in ketamine-anesthetized rats. In addition, the renal responses produced by the intracerebroventricular (i.c.v.) injection of opioid agonists were also examined with use of this anesthetic paradigm. In male Sprague-Dawley rats, the i.v. infusion of isotonic saline (55 µl/min) containing ketamine alone (1.0 mg/kg/min) produced low levels of urine flow rate (6.3 ± 1.3 µl/min/gkw) and urinary sodium excretion (0.28 ± 0.08 µeq/min/gkw). However, after adding xylazine (50 µg/kg/min) to the ketamine infusate, these renal excretory responses were significantly augmented. Steady-state levels of urine flow rate and urinary sodium excretion were attained approximately 120 min after starting the xylazine infusion and were similar in magnitude to the levels of water and sodium excretion previously observed in untreated, conscious rats. In ketamine/xylazine-anesthetized rats, the i.c.v. injection of the mu opioid agonist, dermorphin (0.1 nmol/kg), or the kappa opioid agonist, U-50488H (1 µg total), produced profound and concurrent diuretic and antinatriuretic responses. The pattern (direction and magnitude) of these opioid-induced renal excretory responses was similar to those previously reported in conscious rats. Together, these results indicate that the i.v. infusion of xylazine enhances the renal excretion of water and sodium in ketamine-anesthetized rats. Moreover, the renal responses produced by i.c.v. administration of opioids are similar in ketamine/xylazine-anesthetized and conscious rats. Thus, it appears that the ketamine/xylazine infusion protocol may provide a valid and useful approach to investigate various aspects of the central opioid control of renal function in rats during experimental procedures that require anesthesia.

Copyright © by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
S. Strassburg, S. D. Anker, T. R. Castaneda, L. Burget, D. Perez-Tilve, P. T. Pfluger, R. Nogueiras, H. Halem, J. Z. Dong, M. D. Culler, et al.
Long-term effects of ghrelin and ghrelin receptor agonists on energy balance in rats
Am J Physiol Endocrinol Metab, July 1, 2008; 295(1): E78 - E84.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
K.-H. Lee, B.-H. Ko, J.-Y. Paik, K.-H. Jung, Y. S. Choe, Y. Choi, and B.-T. Kim
Effects of Anesthetic Agents and Fasting Duration on 18F-FDG Biodistribution and Insulin Levels in Tumor-Bearing Mice
J. Nucl. Med., September 1, 2005; 46(9): 1531 - 1536.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. B. Gottlieb, K. J. Varner, V. A. Kenigs, A. M. Cabral, and D. R. Kapusta
Differential Cardiovascular and Renal Responses Produced by Microinjection of the {kappa}-Opioid U-50488H [(trans-3,4-Dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-benzene-acetamide) Methane Sulfonate] into Subregions of the Paraventricular Nucleus
J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 678 - 685.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
R. G. Menegaz, D. R. Kapusta, H. Mauad, and A. de Melo Cabral
Activation of {alpha}2-receptors in the rostral ventrolateral medulla evokes natriuresis by a renal nerve mechanism
Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2001; 281(1): R98 - R107.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
D. B. Jennings and H. J. Lockett
Angiotensin stimulates respiration in spontaneously hypertensive rats
Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2000; 278(5): R1125 - R1133.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
R. G. Menegaz, D. R. Kapusta, and A. M. Cabral
Role of intrarenal alpha 2-adrenoceptors in the renal responses to xylazine in rats
Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2000; 278(4): R1074 - R1081.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
A. D. M. Cabral, D. R. Kapusta, V. A. Kenigs, and K. J. Varner
Central alpha 2-receptor mechanisms contribute to enhanced renal responses during ketamine-xylazine anesthesia
Am J Physiol Regulatory Integrative Comp Physiol, December 1, 1998; 275(6): R1867 - R1874.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.